Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial
Jetty A.M. Weijers(Radboud University Nijmegen), Carla M.L. van Herpen(Radboud University Nijmegen), Wim van Boxtel(Radboud University Nijmegen), Gerald W. Verhaegh(Radboud University Nijmegen), Marjolijn J. L. Ligtenberg(Radboud University Nijmegen), Maike J.M. Uijen(Radboud University Nijmegen), Jack A. Schalken(Radboud University Nijmegen), Adriana C. H. van Engen–van Grunsven(Radboud University Nijmegen), C.M.L. Driessen(Radboud University Nijmegen), Tessa J.J. de Bitter(Radboud University Nijmegen)
Cited by 4
Related Papers
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1
|Nature Genetics|2008|818
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers
|Journal of Medical Genetics|2015|567
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles
|Journal of Extracellular Vesicles|2021|410
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study
|The Lancet Oncology|2010|293